Marco Moschini

@UroDocAsh @ParamMariappan @LAUrology_NL @achoud72 @MRoupret @joanfundi @LauraBukavinaMD @jteoh_hk @paolo_gontero @BenjaminPradere Missing you, will follow from Milano!

Happening soon: ☄️ Rapid Fire Debates: common problems and controversies in #BladderCancer ; 9th Edition Orange Area eURO 2: #EAU26 @ParamMariappan @LAUrology_NL @achoud72 @MRoupret @joanfundi @LauraBukavinaMD @UroMoschini @jteoh_hk @paolo_gontero @BenjaminPradere @BogdanaSchmidt @MattGalsky @NehaVapiwala @tompowles1 #UroTwitter

New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C_6tuO0S… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

🔬✨ Discover the surgical innovations reshaping bladder cancer care on a new Global Perspectives webinar on SIU Academy! Join top global experts for this informative session on cutting-edge resection techniques, robotic & open radical cystectomy, and real-world strategies to improve outcomes in MIBC. Watch open access on SIU Academy: bit.ly/3Z3sInF @fkorkes @jteoh_hk @UroMoschini @SimonemorraMD

What a lovely memento of the #BLADDR25 family. Looking forward to #BLADDR26 in #Amsterdam - come & join us - Dec 2-5 2026! @mirrorsmed @issecam #PROSCA25 #RENALC25

Join us for an interactive seminar on 'Shaping the future: advancing HR-NMIBC management beyond BCG' live from #EMUC25. Register for free here 👉 ecancer.org/EMUC #bladder #urology #Oncology @LAUrology_NL @UroMoschini @evanguelosx

Fantastic #bladdercancer session at #EMUC2025 with a brilliant discussion and a truly stellar panel. So much is chanhing with new treatments, and urologists need to be ready for what’s coming next. @Uroweb

🤩Happy to be part of this timely collaborative multicenter review 🧪The role of ICIs in #NMIBC 📰Just published in @Cancers_MDPI @MDPIOpenAccess 👓Read it: t.ly/gYKQp ✍️@evanguelosx @BenjaminPradere @UroMoschini among others

📢 New SOC for MIBC #ESMO25 Dr. Christof Vulsteke presents KEYNOTE-905: 🚫 No cisplatin? No problem. EV+pembro delivers. 👥 n=344 cis-ineligible MIBC (80% renal impairment, 15% ECOG 2) 🔹 EFS HR 0.40 | OS HR 0.50 🔹 pCR: 57.1% vs 8.6% (ITT, non-op = non-responders) 🔹 No ↑ surgical complications ✅ 1st phase 3 trial showing OS benefit in this population| Unprecedented pCR↑ @urotoday @myESMO

In anticipation of #esmo2025 please find a perfect summary of #bladdercancer trials made by our @UroOnc fellow superstar @hjwang26 .. looking forward to 📊🧑‍💻 ALBAN, POTOMAC @IBCG_BladderCA @CleClinicUro ..

Explore the current definitions, treatment paradigms, & clinical dilemmas of NMIBC in this new #UROwebinar! The experts will address optimal risk stratification, tx duration, & future therapeutic directions. Register here 👇 #1965" target="_blank" rel="nofollow noopener">webinars.uroweb.org/EAU/webinars/#… @LAUrology_NL @UroMoschini

The Urothelial Cancer Update 2025 is officially underway. Esteemed experts are on stage sharing the latest advancements in diagnosis and treatment. ​What has been the most impactful session for you so far? Let us know in the comments! 👇 @cittasalute_to @unito @UroMolinette

@steffiyuen @drkemalsarica Congrats!!

😳Pleasant surprise appointment at CUAstone2025 by Prof Zeng & Ye & @drkemalsarica as IAU youth committee vice chairman!!! We should unite to showcase technology and our work for better outcomes! 🗓️First join us at International Alliance of Urolithiasis 2025 #IAU2025 @Doha 🦾Prof Ng showcasing our work 🤖 robotic RIRS with #FANS 🪭 😎Exciting new new new novel stuff from #CUAstone2025 … getting my hands on all!!!

Agree with @shilpaonc amazing growth of @IBCG_BladderCA with global mission bringing experts together to develop guidelines based on evidence & consensus! @UrogerliMD @UroMoschini @spsutkaMD @MaxKates @siadaneshmand @shilpaonc @SpiessPhilippe @WesKassouf @AndreaNecchi @UroDocAsh

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25! Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided by the patient voice. Both topics reflect our @IBCG_BladderCA mission: to create real-world solutions that improve outcomes and provide practical tools for patients worldwide; through collaboration, collaboration and ... more collaboration! @shilpaonc @UrogerliMD @pjhensley11 @BladderCancerUS @WorldBladderCan @AndreaNecchi @PGrivasMDPhD @siadaneshmand @bbmdmsk @MaxKates @VigneshPackiam @LauraBukavinaMD @drtanws @niyatilobo @MarekBabjuk @joanfundi @RobertoContieri @mouwlab @OAlhalabiMD @urotoday @WesKassouf @SimaPorten @UroMoschini @LAUrology_NL @AStenzl @Agarwal_CaB @marigfern @spsutkaMD @jteoh_hk @Heer_Lab @SpiessPhilippe @SWilliams_MD @achoud72 @paolo_gontero @JanetKukreja @BenjaminPradere @GustavoVillold4 @TomFlaigMD @DrByronLee @KKBree @gautiermarcq @LiangChengMD @h_alahmadie @djmcconkey @BogdanaSchmidt @bkonety

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/43A7qRH

@UroDocAsh Agree. In my opinion the disadvantage is regarding reconstruction: for neobladder is not possible to adeguately prepare the urethra and I prefer to not offer neobladder in these patients (I suppose functional outcomes are consistenly worse) for bricker increased risks of stenosis

I often hear that post-TMT cystectomy is “fraught with complications even in experienced hands.” That hasn’t been my experience. With the right principles and disciplined technique, these cases can be remarkably straightforward. Maybe I’m delusional - but curious to hear what others think. What’s been your experience? @siadaneshmand @drgaganprakash @joanfundi @bbmdmsk @UrogerliMD @MarekBabjuk @MariaJRibal @AlisonBirtle @ParamMariappan @LauraBukavinaMD @SimaPorten @nnavai @MaxKates @SpiessPhilippe @paolo_gontero @VedangMurthy #OncSurgery @MRoupret @garysteinbergmd

A honor to present the latest updates on urinary #biomarkers in HG NMIBC follow-up at the @Uroweb #uroonco congress. Have you read the DaBlaCa-15 Trial paper published in @EUplatinum? Check that out Thanks inviting me @foxal72 @UroMoschini and to my opponent @evanguelosx 🙏🏻

A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol authors.elsevier.com/c/1l7pU_wtP00L… There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/43A7qRH

Complete vs partial TURBT for muscle-invasive #BladderCancer treatment. @UroLiedberg, @UroMoschini & @BenjaminPradere join @UroDocAsh in a discussion on the extent of transurethral resection of bladder tumor needed in #MIBC. They debate the value of complete resection when considering bladder-sparing approaches, neoadjuvant therapy, and clinical trials. #WatchNow on UroToday > bit.ly/42nD3NM